ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
企業コードANIP
会社名ANI Pharmaceuticals Inc
上場日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
従業員数897
証券種類Ordinary Share
決算期末May 04
本社所在地210 Main Street West
都市BAUDETTE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号56623
電話番号12186343500
ウェブサイトhttps://www.anipharmaceuticals.com/
企業コードANIP
上場日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし